A simple, yet highly accurate, QSAR model captures the complement inhibitory activity of compstatin

被引:11
作者
Mulakala, Chandrika
Lambris, John D.
Kaznessis, Yiannis [1 ]
机构
[1] Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Digital Technol Ctr, Minneapolis, MN 55455 USA
[3] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
基金
美国国家卫生研究院;
关键词
QSAR; structure-activity relationships; compstatin; C3; complement;
D O I
10.1016/j.bmc.2006.12.015
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Compstatin is a 13-residue cyclic peptide inhibitor of complement activation that was originally identified through phage-mediated presentation of a peptide library to C3b. Recent efforts to improve its activity have led to a rich dataset of complement analogs, with the most active analog being similar to 260 times more active than the parent compstatin. In the present work, a highly transparent quantitative structure-activity relationship model (R-adj(2) = 0.89) with four parameters is presented that captures important physico-chemical and geometrical properties of the analog molecules with regard to activity. The number of aromatic bonds and hydrophobicity of the fourth residue of compstatin correlated strongly with activity. Also important were the hydrophobic patch size near the disulfide bond and the solvent-accessible surface area occupied by nitrogen atoms of basic amino acid residues. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1638 / 1644
页数:7
相关论文
共 23 条
[1]   Complement-dependent proinflammatory properties of the Alzheimer's disease β-peptide [J].
Bradt, BM ;
Kolb, WP ;
Cooper, NR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (03) :431-438
[2]  
*CHEM COMP GROUP, 2005, MOE MOL OP ENV
[3]   Pitfalls in QSAR [J].
Cronin, MTD ;
Schultz, TW .
JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM, 2003, 622 (1-2) :39-51
[4]  
DeLano W. L., 2002, PYMOL
[5]   Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts [J].
Fiane, AE ;
Mollnes, TE ;
Videm, V ;
Hovig, T ;
Hogåsen, K ;
Mellbye, OJ ;
Spruce, L ;
Moore, WT ;
Sahu, A ;
Lambris, JD .
XENOTRANSPLANTATION, 1999, 6 (01) :52-65
[6]   Prolongation of ex vivo-perfused pig xenograft survival by the complement inhibitor compstatin [J].
Fiane, AE ;
Mollnes, TE ;
Videm, V ;
Hovig, T ;
Hogåsen, K ;
Mellbye, OJ ;
Spruce, L ;
Moore, WT ;
Sahu, A ;
Lambris, JD .
TRANSPLANTATION PROCEEDINGS, 1999, 31 (1-2) :934-935
[7]   Structures of complement component C3 provide insights into the function and evolution of immunity [J].
Janssen, BJC ;
Huizinga, EG ;
Raaijmakers, HCA ;
Roos, A ;
Daha, MR ;
Nilsson-Ekdahl, K ;
Nilsson, B ;
Gros, P .
NATURE, 2005, 437 (7058) :505-511
[8]   THERAPEUTIC USES OF RECOMBINANT COMPLEMENT PROTEIN INHIBITORS [J].
KALLI, KR ;
HSU, P ;
FEARON, DT .
SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1994, 15 (04) :417-431
[9]   Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin [J].
Katragadda, Madan ;
Magotti, Paola ;
Sfyroera, Georgia ;
Lambris, John D. .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (15) :4616-4622
[10]   THE COMPLEMENT-SYSTEM IN MYOCARDIAL ISCHAEMIA/REPERFUSION INJURY [J].
KILGORE, KS ;
FRIEDRICHS, GS ;
HOMEISTER, JW ;
LUCCHESI, BR .
CARDIOVASCULAR RESEARCH, 1994, 28 (04) :437-444